Travere Hits Profit on FILSPARI Sales, But FDA Scrutiny Looms Large

SAN DIEGO, CA – February 19, 2026 – Travere Therapeutics (NASDAQ: TVTX) announced a significant financial turnaround, posting a profitable fourth quarter for 2025 fueled by surging sales of its rare kidney disease drug, FILSPARI. However, the positive bottom line was tempered by revenues that fell short of analyst expectations and an impending high-stakes regulatory decision, creating a nuanced picture of a company at a pivotal crossroads.

The biopharmaceutical firm reported a GAAP net income of $2.7 million for the fourth quarter, a dramatic reversal from the $60.3 million net loss recorded in the same period of 2024. This performance was largely driven by the robust commercial uptake of FILSPARI. For the full year, the company substantially narrowed its net loss to $25.5 million from a staggering $321.5 million in 2024. Despite the positive earnings surprise, the market's reaction was muted, with the company's stock seeing a slight dip in after-hours trading as investors weighed the profitability against a revenue miss.

FILSPARI's Commercial Power

The clear engine behind Travere's improved financial health is FILSPARI (sparsentan), a treatment for primary immunoglobulin A nephropathy (IgAN), a rare kidney disease that can lead to kidney failure. U.S. net product sales for FILSPARI skyrocketed, reaching $103.3 million in the fourth quarter of 2025, a 108% increase over the prior-year period. Full-year sales for the drug climbed 144% to $322.0 million.

Evidence of strong market adoption was highlighted by the 908 new patient start forms received in the fourth quarter, indicating continued demand from both new and repeat prescribers. In the company's press release, CEO Eric Dube, Ph.D., emphasized the drug's success, stating, “In IgA nephropathy, continued adoption of FILSPARI underscores its foundational positioning and the positive impact we are delivering for patients and physicians.”

Despite its strong launch, FILSPARI operates in an increasingly competitive IgAN market. It faces rivals such as Calliditas' fully approved TARPEYO and Novartis' recently approved FABHALTA. Travere asserts that FILSPARI's profile as a once-daily, oral, non-immunosuppressive therapy differentiates it from competitors. The company is also pursuing global expansion through strategic partnerships. Its European partner, CSL Limited, has already launched the drug in several countries, including Germany and the UK, and its Japanese partner, Chugai Pharmaceutical, is expected to submit a New Drug Application in 2026.

The High-Stakes Gamble on FSGS

While celebrating its success in IgAN, Travere's future growth trajectory is heavily tied to expanding FILSPARI's label to include Focal Segmental Glomerulosclerosis (FSGS), another serious kidney disorder with no currently approved pharmacological treatments. A potential approval would make FILSPARI the first-ever therapy specifically indicated for FSGS, opening a significant new market.

All eyes are on the FDA's upcoming Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The path to this date has been fraught with uncertainty. The FDA initially set a January date but extended its review by three months after deeming additional data submitted by Travere to be a "Major Amendment." The news of the delay caused the company's stock to fall sharply earlier in the year, highlighting the binary risk associated with the decision.

In a potentially positive sign, the FDA later informed Travere that a planned advisory committee meeting to discuss the application was no longer necessary, which can sometimes indicate that regulators have sufficient data to make a decision. However, the application is based on complex clinical data. The pivotal Phase 3 DUPLEX study, while demonstrating significant reductions in proteinuria—a key marker of kidney damage—did not meet its primary endpoint of kidney function preservation over 108 weeks. The company argues that the totality of the data, including higher rates of remission and a lower rate of end-stage kidney disease compared to the control arm, supports approval in a disease with no other options.

A Pipeline of Hope for Rare Diseases

Beyond FILSPARI, Travere is advancing a pipeline focused on other rare conditions, reinforcing its long-term strategy. A key program is pegtibatinase, a potential first-in-class enzyme replacement therapy for classical Homocystinuria (HCU). HCU is a debilitating genetic metabolic disorder that leads to a toxic buildup of homocysteine, causing severe complications including blood clots, skeletal abnormalities, and cognitive impairment.

Current management for HCU is incredibly burdensome, often involving a lifelong, highly restrictive low-protein diet and medical formulas that patients find difficult to tolerate. Pegtibatinase has the potential to become the first disease-modifying therapy for HCU, offering hope for a dramatically improved quality of life.

The company recently restarted enrollment activities for its pivotal Phase 3 HARMONY Study of the drug, a crucial step toward bringing this potential therapy to a patient community with immense unmet needs. The advancement of the HCU program underscores Travere's commitment to building a diversified portfolio aimed at transforming the standard of care in rare diseases.

As Travere moves into 2026, it stands as a company that has successfully navigated the difficult path to commercialization and profitability. Yet, its future valuation and position as a leader in rare disease therapeutics will be profoundly shaped by the challenges ahead: maintaining momentum in a competitive IgAN market and, most critically, securing the landmark FDA approval for FILSPARI in FSGS.